Physician profile
Ing I Lam
NPI 1750365482
$4,749.85
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,269 · 2020: $830 · 2021: $1,124 · 2022: $1,029 · 2023: $498.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $498.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $497.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $833.58 | 2021-2023 | |
| Allergan, INC. | $754.08 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $596.32 | 2019-2023 | Trintellix |
| Otsuka America Pharmaceutical, INC. | $464.87 | 2019-2023 | Rexulti |
| Sunovion Pharmaceuticals INC. | $283.55 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $265.96 | 2019-2023 | Invega Sustenna, Invega Trinza |
| Lundbeck LLC | $265.52 | 2019-2023 | Rexulti |
| Alkermes, INC. | $223.90 | 2021-2023 | Aristada, Lybalvi |
| Arbor Pharmaceuticals, INC. | $151.88 | 2019-2020 | |
| Corium, LLC | $135.58 | 2021-2023 | Azstarys |
| Ironshore Pharmaceuticals INC. | $127.55 | 2019-2023 | Jornay Pm |
| Shire North American Group INC | $124.12 | 2019 | |
| Tris Pharma INC | $121.97 | 2019-2023 | Dyanavel Xr |
| Neos Therapeutics, LP | $110.47 | 2019-2020 | |
| Adlon Therapeutics L.P. | $72.03 | 2019-2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch Health US, LLC | $65.64 | 2020-2022 | |
| Jazz Pharmaceuticals INC. | $64.57 | 2019-2022 | |
| Supernus Pharmaceuticals, INC. | $39.88 | 2022-2023 | Qelbree |
| Vertical Pharmaceuticals, LLC | $35.02 | 2019 | |
| Idorsia Pharmaceuticals US INC | $13.36 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ing Lam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.